TScan Therapeutics, Inc. (NASDAQ:TCRX) Director Barbara Klencke has recently increased her stake in the company, purchasing shares valued at a total of $26,450. The transaction, which took place on September 23, involved the acquisition of 5,000 shares of TScan’s voting common stock at a price of $5.29 per share.
This purchase brings Klencke’s direct ownership in TScan Therapeutics to 45,000 shares. Additionally, it’s noteworthy that Klencke is associated with the Klencke Huestis Trust, which holds 25,000 shares of the company. According to a footnote in the filing, Klencke serves as co-trustee with her spouse for the trust and disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.
TScan Therapeutics, headquartered in Waltham, Massachusetts, operates in the biotechnology sector, focusing on the development of biological products. The latest insider transaction provides an update on the movements of the company’s stock by its directors, which is often of interest to investors tracking ownership trends and confidence within the company.
The reported transactions were filed with the Securities and Exchange Commission and were publicly disclosed on September 24, following the standard regulatory requirements for insider transactions. Barbara Klencke’s signature was affixed to the document, confirming the accuracy and completion of the reported data.
InvestingPro Insights
TScan Therapeutics, Inc. (NASDAQ:TCRX) has recently seen significant insider activity, with Director Barbara Klencke increasing her stake in the company. As investors evaluate the confidence insiders have in their company, it’s crucial to consider the company’s financial health and market position. According to InvestingPro data, TScan Therapeutics currently holds a market capitalization of approximately $271.23 million. Despite challenging market conditions, TScan’s stock has demonstrated resilience over the past year, with a 96.23% return, although recent trends show a dip with a 10.81% decline year-to-date as of 2024.
InvestingPro Tips suggest keeping an eye on TScan’s valuation metrics. The company’s Price to Earnings (P/E) Ratio stands at -2.61, reflecting its current earnings challenges. Additionally, the Price to Book (P/B) Ratio as of the last twelve months ending in Q2 2024 is 1.06, which may indicate the stock is reasonably valued in terms of its assets and liabilities.
Investors should also note that TScan’s revenue has declined by 25.65% in the last twelve months as of Q2 2024, a significant consideration for those looking at the company’s growth trajectory. Moreover, the gross profit margin has been reported at -694.11%, a figure that highlights the company’s current difficulties in generating profit from its revenues. These financial metrics are essential for investors to assess the company’s performance and future potential.
For those seeking more comprehensive analysis, InvestingPro offers additional tips on TScan Therapeutics. In fact, there are 12 more InvestingPro Tips available, which can provide investors with a deeper understanding of the company’s financial health and stock performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
